FDA grants priority review to CorMedix's Rezzayo fungal prophylaxis sNDA
Tweet Send to a Friend
CorMedix Therapeutics (Nasdaq: CRMD) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




